Publications by authors named "L D Karpenko"
Article Synopsis
- - The vaccinia virus has been historically used as a smallpox vaccine, but due to its reactogenicity, WHO recommended discontinuation after smallpox was eradicated, leading to a rise in orthopoxvirus infections, notably the 2022 monkeypox epidemic.
- - Researchers developed modified VACV strains, LAD and LADA, with specific genetic alterations to reduce reactogenicity while enhancing the immune response compared to the original L strain.
- - Both LAD and LADA strains demonstrated superior cellular immune responses and higher levels of VACV-specific IgG in vaccinated mice, indicating their potential as safer and more effective vaccines against orthopoxvirus infections.
The mouse paramyxovirus Sendai, which is capable of limited replication in human bronchial epithelial cells without causing disease, is well suited for the development of vector-based intranasal vaccines against respiratory infections, including SARS-CoV-2. Using the Moscow strain of the Sendai virus, we developed a vaccine construct, Sen-Sdelta(M), which expresses the full-length spike (S) protein of the SARS-CoV-2 delta variant. A single intranasal delivery of Sen-Sdelta(M) to Syrian hamsters and BALB/c mice induced high titers of virus-neutralizing antibodies specific to the SARS-CoV-2 delta variant.
View Article and Find Full Text PDFThe removal of double-stranded RNA (dsRNA) contaminants during in vitro mRNA synthesis is one of the technological problems to be solved. Apparently, these contaminants are the result of the T7 RNA polymerase side activity. In this study, we used a modified method of mRNA purification based on the selective binding of dsRNA to cellulose in ethanol-containing buffer.
View Article and Find Full Text PDFWe studied a needle-free jet injection delivery of an experimental mRNA vaccine encoding the receptor-binding domain of the SARS-CoV-2 S protein (mRNA-RBD). Immunization of BALB/c mice with mRNA-RBD by a needle-free jet injector induced high levels of antibodies with virus-neutralizing activity and a virus-specific T-cell response. The immune response was low in the group of mice that received intramuscular injection of mRNA-RBD.
View Article and Find Full Text PDFArticle Synopsis
- The H5N8 avian influenza virus poses a risk to bird populations and potential human health concerns, necessitating the development of a safe and effective vaccine.
- Researchers created an experimental pVAX-H5 DNA vaccine that encodes a modified version of the virus's hemagglutinin and tested it on mice, resulting in a strong antibody and T-cell response.
- Both liquid and lyophilized versions of the pVAX-H5 vaccine provided complete protection for mice against lethal influenza A virus challenges, showing promise as a candidate for combating H5N8.